| A systematic review of miR-29 in cancer JJ Kwon, TD Factora, S Dey, J Kota Molecular Therapy-Oncolytics 12, 173-194, 2019 | 198 | 2019 |
| Pancreatic cancer: Stroma and its current and emerging targeted therapies J Kota, J Hancock, J Kwon, M Korc Cancer letters 391, 38-49, 2017 | 175 | 2017 |
| Synthetic lethal interaction of SHOC2 depletion with MEK inhibition in RAS-driven cancers R Sulahian, JJ Kwon, KH Walsh, E Pailler, TL Bosse, M Thaker, ... Cell reports 29 (1), 118-134. e8, 2019 | 75 | 2019 |
| Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential JJ Kwon, JA Willy, KA Quirin, RC Wek, M Korc, XM Yin, J Kota Oncotarget 7 (44), 71635, 2016 | 70 | 2016 |
| Pathophysiological role of microRNA-29 in pancreatic cancer stroma JJ Kwon, SC Nabinger, Z Vega, SS Sahu, RK Alluri, Z Abdul-Sater, Z Yu, ... Scientific reports 5 (1), 11450, 2015 | 69 | 2015 |
| Structure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex JJ Kwon, B Hajian, Y Bian, LC Young, AJ Amor, JR Fuller, CV Fraley, ... Nature 609 (7926), 408-415, 2022 | 46 | 2022 |
| miR-29a is repressed by MYC in pancreatic cancer and its restoration drives tumor-suppressive effects via downregulation of LOXL2 S Dey, JJ Kwon, S Liu, GA Hodge, S Taleb, TA Zimmers, J Wan, J Kota Molecular Cancer Research 18 (2), 311-323, 2020 | 29 | 2020 |
| Safety and efficacy of AAV retrograde pancreatic ductal gene delivery in normal and pancreatic cancer mice KA Quirin, JJ Kwon, A Alioufi, T Factora, CJ Temm, M Jacobsen, ... Molecular therapy Methods & clinical development 8, 8-20, 2018 | 29 | 2018 |
| Loss of miR-29a/b1 promotes inflammation and fibrosis in acute pancreatitis S Dey, LM Udari, P RiveraHernandez, JJ Kwon, B Willis, JJ Easler, ... JCI insight 6 (19), 2021 | 25 | 2021 |
| A leucine-rich repeat protein provides a SHOC2 the RAS circuit: a structure-function perspective JJ Kwon, WC Hahn Molecular and Cellular Biology 41 (4), e00627-20, 2021 | 22 | 2021 |
| Sparse dictionary learning recovers pleiotropy from human cell fitness screens J Pan, JJ Kwon, JA Talamas, AA Borah, F Vazquez, JS Boehm, ... Cell systems 13 (4), 286-303. e10, 2022 | 21 | 2022 |
| Systematic profiling of conditional degron tag technologies for target validation studies DP Bondeson, Z Mullin-Bernstein, S Oliver, TA Skipper, TC Atack, N Bick, ... Nature communications 13 (1), 5495, 2022 | 17 | 2022 |
| VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system J So, NW Mabe, B Englinger, KH Chow, SM Moyer, S Yerrum, MC Trissal, ... JCI insight 7 (19), 2022 | 15 | 2022 |
| CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies JH Hwang, R Arafeh, JH Seo, SC Baca, M Ludwig, TE Arnoff, L Sawyer, ... Elife 11, e73223, 2022 | 11 | 2022 |
| Target-driven machine learning-enabled virtual screening (TAME-VS) platform for early-stage hit identification Y Bian, JJ Kwon, C Liu, E Margiotta, M Shekhar, AE Gould Frontiers in Molecular Biosciences 10, 1163536, 2023 | 2 | 2023 |
| Methods for microRNA profiling in cancer S Yarlagadda, A Thota, R Bansal, J Kwon, M Korc, J Kota Epigenetics and Gene Expression in Cancer, Inflammatory and Immune Diseases …, 2017 | 2 | 2017 |
| On knowing a gene: A distributional hypothesis of gene function JJ Kwon, J Pan, G Gonzalez, WC Hahn, M Zitnik Cell Systems, 2024 | 1 | 2024 |
| Identification of MYC as a novel repressor of miR-29 in pancreatic ductal adenocarcinoma J Kwon, K Quirin, T Factora, J Kota Cancer Research 78 (13_Supplement), 528-528, 2018 | 1 | 2018 |
